Influenza A viruses (IAVs) remain serious threats to public health because of the shortage of effective means of control. Developing more effective virus control modalities requires better understanding of virus-host interactions. It has previously been shown that IAV induces the production of kynurenine, which suppresses T-cell responses, enhances pain hypersensitivity and disturbs behaviour in infected animals. However, the regulation of kynurenine biosynthesis during IAV infection remains elusive. Here we showed that IAV infection induced expression of interferons (IFNs), which upregulated production of indoleamine-2,3-dioxygenase (IDO1), which catalysed the kynurenine biosynthesis. Furthermore, IAV attenuated the IDO1 expression and the production of kynurenine through its NS1 protein. Interestingly, inhibition of viral replication prior to IFN induction limited IDO1 expression, while inhibition after did not. Finally, we showed that kynurenine biosynthesis was activated in macrophages in response to other stimuli, such as influenza B virus, herpes simplex virus 1 and 2 as well as bacterial lipopolysaccharides. Thus, the tight regulation of the kynurenine biosynthesis by host cell and, perhaps, pathogen might be a basic signature of a wide range of host-pathogen interactions, which should be taken into account during development of novel antiviral and antibacterial drugs.
Influenza A viruses (IAVs) remain serious threats to public health because of the shortage of effective means of control. Developing more effective virus control modalities requires better understanding of virus-host interactions. It has previously been shown that IAV induces the production of kynurenine, which suppresses T-cell responses, enhances pain hypersensitivity and disturbs behaviour in infected animals. However, the regulation of kynurenine biosynthesis during IAV infection remains elusive. Here we showed that IAV infection induced expression of interferons (IFNs), which upregulated production of indoleamine-2,3-dioxygenase (IDO1), which catalysed the kynurenine biosynthesis. Furthermore, IAV attenuated the IDO1 expression and the production of kynurenine through its NS1 protein. Interestingly, inhibition of viral replication prior to IFN induction limited IDO1 expression, while inhibition after did not. Finally, we showed that kynurenine biosynthesis was activated in macrophages in response to other stimuli, such as influenza B virus, herpes simplex virus 1 and 2 as well as bacterial lipopolysaccharides. Thus, the tight regulation of the kynurenine biosynthesis by host cell and, perhaps, pathogen might be a basic signature of a wide range of host-pathogen interactions, which should be taken into account during development of novel antiviral and antibacterial drugs.
Introduction
Influenza A viruses (IAV) are important human pathogens that cause global epidemics and pandemics (www. who.int). It is estimated that IAVs are responsible for up to half a million deaths a year [1] . The successful recovery from viral infection largely depends on an efficient activation of innate and adaptive immune responses [2] . Metabolic responses are a part of this mechanism [3] . In particular, infected organisms reprogramme their amino acid, lipid and sugar metabolism in order to produce immune-and neuro-mediators, as well as to lower levels of energy and viral building blocks [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .
Alteration of the kynurenine pathway (KP) of tryptophan metabolism is one of the metabolic responses to IAV infection [14] . The major enzymes and substrates of the KP are shown in Fig. 1 . The enzymatic reactions proceed from tryptophan through a number of steps, with some of the key metabolic intermediates which are kynurenine, 3-hydroxyanthranilate and quinolinate [15] . These compounds can modulate the activity of the immune and central nervous systems. The first enzymes of the KP are indoleamine-pyrrole 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase (TDO2) [16] . TDO2 is mainly expressed in hepatocytes, whereas IDO1 is found in most cell types, including macrophages. The expression of IDO1 was shown to be upregulated in response to IAV infection through interferon (IFN) pathway [12, 17, 18] . Moreover, the overexpression of IDO1 was associated with cytokine overproduction, suppression of T-cell response, pain hypersensitivity and behavioural disturbances [11, [19] [20] [21] [22] [23] . The neurological symptoms were linked to high levels of kynurenine, the product of IDO1 catalysis. This strongly indicates that IDO1 and kynurenine are important components of the host response to IAV infection.
Here we show that the IFN-mediated transcription of IDO1 and production of kynurenine was upregulated in response to IAV infection in mouse lungs and human primary macrophages. However, IAV nonstructural protein 1 (NS1) attenuated the expression of IFNs and IDO1, and several residues within the NS1 RNA/DNA-binding (RBD) and effector (ED) domains were implicated in this process. Furthermore, we demonstrated that inhibitors of IAV entry, but not of viral RNA transcription/replication, prevented the activation of IDO1 expression and the production of kynurenine. Finally, we showed that KP was activated in response to herpes simplex virus (HSV) 1 and 2, and influenza B virus infections, as well as to E. coli lipopolysaccharides (LPS) stimulation. Based on these results, we conclude that metabolic reprogramming of KP could be a basic feature of different pathogen-host interactions, which should be taken into consideration during the antiviral/antibacterial drug development process.
Results

IAV activates KP in mouse lungs
We performed recently transcriptomics experiment using RNA isolated from lung samples of A/WSN/ 1933(H1N1)-and mock-infected mice at day 3 post infection [24] . Our analysis identified many differentially expressed IFN genes (fold-change (FC) > 4 and < À4) and one gene, which belonged to the tryptophan metabolism according to the REACTOME pathway database ( Fig. 2A) . IDO1 expression was upregulated more than eight folds in the lungs of all three IAVinfected animals (average FC = 11.3; P = 5 9 10 À7 ).
To test whether tryptophan metabolism was altered during IAV infection, we analysed eight tryptophan metabolites in lung homogenates prepared from WSNand mock-infected mice at day 3 post infection using liquid chromatography with mass spectrometry (LC-MS)/MS [25] . We detected seven metabolites, including tryptophan, kynurenine, kynurenic acid, 3-hydroxyanthranilic acid (3-HAA), 5-hydroxytryptophan (5-HT), nicotinamide adenine dinucleotide (NAD) and 5-hydroxyindole-3-acetic acid (5-HIAA; Fig. 2B ). Importantly, only the level of kynurenine was significantly elevated in IAV-infected animals in comparison to the control group (average FC = 6.2; P = 2 9 10 À9 ).
Thus, WSN infection activated the IFN-mediated expression of IDO1 and the production of kynurenine in mouse lungs, indicating that KP of tryptophan metabolism is a component of host responses during IAV infection.
IAV and several other viruses as well as bacterial LPS activate cellular KP in macrophages
The mammalian lung is composed of several cell types, from which alveolar macrophages, epithelial and dendritic cells represent the primary targets for IAV infection. Human peripheral blood mononuclear cells (PBMC)-derived macrophages represent a reliable model system for studying IAV-host cell interactions [26] . Macrophages isolated from healthy donors are susceptible to influenza A(H1N1) and A(H3N2) virus infection as could be judged from the cell viability assay (Fig. 3A) . Our gene expression analysis indicated that infected cells overexpressed several IFN genes, including IFNB1 and IFNG as well as IDO1 (average FC = 3.7), but not other genes of KP (Fig. 3B) . RTqPCR analysis confirmed these results (Fig. 3C ).
Immunoblot analyses also showed that expression of IDO1, IFNB1 as well as viral M1, NS1 and NP was upregulated in infected cells (Fig. 3D) . In order to understand whether the KP was altered during IAV infection, we analysed eight tryptophan metabolites in the macrophage culture medium at 24 h after IAV or mock infection. We found that the level of kynurenine was increased by around 10-fold in response to IAV infection (average FC = 9.8), whereas the level of kynurenic acid, tryptophan, 5-HT and NAD remained almost unaffected, and 3-hydroxykynurenine, 3-HAA and 5-HIAA were undetectable (Fig. 3E) . Altogether, these results indicate that the IDO1 expression and kynurenine production were upregulated in response to IAV infection in human primary macrophages.
We next tested whether infection with other viruses or stimulation with viral double-stranded RNA (dsRNA), or bacterial LPS could activate the kynurenine biosynthesis in macrophages. We infected macrophages with influenza B, echovirus 6 (EV6), EV1, HSV1, HSV2 or treated them with bacterial LPS or viral dsRNA. Gene expression analysis, followed by RT-qPCR as well as LC-MC/MC analysis showed that the expression of IDO1 and kynurenine production was upregulated (FC IDO1 > 2.6; FC kynurenine > 2.8) in influenza B-, HSV1-and HSV2-infected and LPS-stimulated cells, but not in EV1-, EV6-infected or dsRNA-stimulated macrophages ( Fig. 3B-D) . In particular, IDO1 was expressed by a factor of~100 (H1N1 and H3N2, HSV1 and HSV2) or,~1000 (influenza B; Fig. 3C , top), while IFNB1 was overexpressed by a factor of~10 000 (H1N1 and H3N2),~30 000 (influenza B),~1000 (EV1) or~5000 (EV6, HSV1 and HSV2; Fig. 3C , bottom). Interestingly, the expression of IFNG, IFNB1, as well as several IFNA genes, was also upregulated in these cells. Thus, our results suggest that kynurenine biosynthesis is upregulated in response to different IFNstimulating agents.
Specific IFNs activate KP in infected and noninfected cells
Our gene expression experiments, as well as previous studies, indicated that IFNa, IFNb and IFNc might regulate IDO1-mediated KP [12, 14, 27 ]. Therefore, we tested the effect of different human recombinant IFNs on the transcription of IDO1 and the production of kynurenine in macrophages ( Fig. 4A-D) . We observed that noncytotoxic concentrations of IFNa-2a, IFNa2b, IFNb-1a and IFNb-1b, and especially IFNc, but not IFNΩ1, IFNk (IL28; IL29) upregulated the transcription of IDO1 and the production of kynurenine in comparison with mock-infected cells (FC IDO1 > 180; FC kynurenine > 10; Fig. 4C,D) .
IFNa and IFNc are well-characterized stimuli of IDO1 expression, by contrast to IFNb [12, 14] . To confirm that IAV can activate IFNb-mediated KP, we silenced IFNB1 for 24 h in human retinal pigment epithelial (RPE) cells and infected the cells with influenza A(H1N1) virus or mock (Fig. 5A) . The cell viability of the silenced cells was measured 24 h after infection (Fig. 5B) . We also analysed IFNB1, IDO1 and M1 expression at 8 hpi and kynurenine production at 24 hpi. IFNB1-silencing in H1N1-infected cells indeed reduced the expression of IFNB1 (by about seven-folds) as well as that of IDO1 (by about twofold; Fig. 5C ), resulting in attenuated KP (Fig. 5D) . Interestingly, the expression of viral M1 (as expressed as copy number of viral M segment) was increased by about two-fold in IFNB1-silenced cells, indicating that IFNB1 limited viral replication. Thus, IFNB1 could regulate IDO1-mediated production of kynurenine.
We next tested whether IFNs secreted by infected cells can trigger the kynurenine production in noninfected cells. For this, we performed an experiment schematically depicted in Fig. 6A . In particular, we collected media from IAV-infected macrophages (P1), neutralized IAVs with an anti-HA antibody [28] , diluted the media 20-fold and applied it to noninfected cells (P2). Cell viability assay, gene expression profiling and LC-MS/MS analysis showed that the media from infected P1 cells was not cytotoxic, but it induced the transcription of IDO1 and production of kynurenine in noninfected P2 cells (FC IDO1 > 13; FC kynurenine ≥ 13; Fig. 6B-D) . Interestingly, media from P1 cells also activated synthesis of 3-HAA and kynurenic acid in P2 cells (FC 3-HAA > 56; FC kynurenic acid ≥ 13). In the control experiment, we used media from P2 cells and treated noninfected P3 cells (Fig. 6D ). There was no upregulation of kynurenine production in P3 cells. Thus, IDO1 modulators produced by IAV-infected cells stimulated KP both in infected and noninfected cells, i.e. they had both autocrine and paracrine activity.
Inactivation of IAV NS1 exacerbate KP
IAV suppresses the transcription of many IFN and IFN-stimulated genes (ISGs) through its multifunctional NS1 protein in infected cells (Fig. 7A ) [29] [30] [31] [32] [33] . To understand whether NS1 can antagonize IFNmediated transcription of IDO1 and the production of kynurenine, we infected macrophages with different A (H1N1) strains expressing mutant or wild-type NS1 protein. In particular, we used WSN strains with mutations in the RNA-binding domain (RBD, R38A/ K41A), the effector domain (ED, F103S/M106I and A149V) or the C-terminal region (D221-230) of NS1 [30, 33, 34] . It was shown that these mutations prevent NS1 interactions with dsRNA/DNA, CPSF4, nuclear export machinery or some other cellular and viral factors, and thus suppress the production of IFNs and ISGs [30] [31] [32] [33] 35] . Figure 7B demonstrates that mutant viruses similar to wild-type strain reduced the viability of macrophages. However, infections with IAV strains that carry mutations in RBD or ED but not at the C terminus of NS1, upregulated the expression of IDO1 and the production of kynurenine in comparison to wild-type virus (i.e. the upregulation of IDO1 seems to be about 10-fold for the first three mutants). The levels of IFNB1, in contrast to viral M1 were also upregulated by these strains (Fig. 7C,D) . Thus, inactivation of viral IFN-antagonist NS1 exacerbated KP. gemcitabine and JNJ872) and two IDO1 inhibitors (epacadostat and NLG919), on IDO1 expression and kynurenine production in WSN-and mock-infected macrophages [26, 33, [36] [37] [38] . A schematic representation of the experiment is depicted in Fig. 8A . We found that obatoclax, SNS-032, SaliPhe, gemcitabine and JNJ872, in contrast to epacadostat and NLG919 rescued IAV-infected cells from IAV-mediated death at noncytotoxic concentrations (Fig. 8B) . Moreover, obatoclax, SNS-032, and SaliPhe efficiently reduced IAVinduced transcription of both IFNB1 and IDO1 and production of kynurenine (Fig 8C,D) . By contrast, IAV-induced transcription of both IFNB1 and IDO1 remained unchanged upon JNJ-872 treatment, while gemcitabine slightly increased both of them. These results indicate that the antiviral compounds, which target the virus entry (such as obatoclax, SNS-032 and SaliPhe), and not those targeting later stages of the IAV replication cycle (such as gemcitabine and JNJ-872), may inhibit IAV-stimulated KP. As expected, both IDO1 inhibitors at noncytotoxic concentrations allowed the transcription of IDO1, but not the synthesis of kynurenine, indicating that IDO1 is responsible for kynurenine production in IAV-infected human macrophages.
Discussion
In the present study, we have shown that IAV infection induced IFN-mediated expression of IDO1 in human primary macrophages and mouse lungs. IDO1 overexpression was associated with an increased kynurenine level. Given that kynurenine functions as an immuno-and neuromodulator, its production by IAV-infected cells could contribute to systemic responses of the host to the infection at hand. We have also demonstrated that different IFNs, including IFNc, IFNb and IFNa, played an important role in the activation of KP. However, IAV attenuated the IFN-mediated KP activation, notably through its NS1 protein. Indeed, substitutions that are known to alter the IFN-antagonistic activity of NS1 (R38A/ K41A, F103S/M106I and A149V) resulted in overexpression of both IFNB1 and IDO1 and augmented the level of kynurenine. Thus, we have provided novel insight in the regulation of host responses and virus counterresponses in IAV-infected cells.
Moreover, we observed that the KP was activated in macrophages in response to infection with influenza B, HSV1, HSV2 strains or stimulation with bacterial LPS. Also other important human pathogens (such as, human immunodeficiency virus, hepatitis B virus, hepatitis C virus, cytomegalovirus, Chlamydia psittaci, Toxoplasma gondii and Leishmania donovani) have been shown to activate KP in infected cells [39] . Thus, reprogramming of KP could be a basic mechanism uniting a surprisingly wide range of pathogen-host interactions.
We further demonstrated that antiviral compounds that inhibit IAV entry prevented KP activation. By contrast, antiviral agents that inhibited later stages of virus infection stimulated KP. Given that kynurenine has been reported to trigger pain hypersensitivity during viral infection [11] , antivirals that inhibit IAV entry, as well as a combination of antivirals which inhibit later stages of IAV infection with IDO1 inhibitors, might be used for treatment of severe IAV infections and accompanying neurological symptoms.
Experimental procedures
Viruses and other immune stimuli
Human influenza A/WSN/33(H1N1) strains expressing wild-type (WT), R38A/K41A mutant or truncated NS1 (D221-230) were generated using the WSN eight-plasmidbased reverse genetics system in HEK293T and Vero cells as described previously [25, 33, 40] G224R/E229K NS1 mutants were generated using 12-plasmid-based reverse genetics and were propagated in 11-day-old embryonated chicken eggs at 34°C for 3 days as previously described [25, 30, 41] . Human influenza A/Udorn/ 307/1972 (H3N2) virus was cultured in embryonated hen eggs as described previously [42] . Influenza B/Shandong/7/ 97 virus was grown in the allantoic cavities of 11-day-old embryonated chicken eggs for 3 days at 33°C as described [43] . EV1 (Farouk strain, obtained from the ATCC) was propagated in a monolayer of GMK cells and purified using an overall scheme similar to that described previously [44] . EV6 was propagated in a monolayer of A549 cells as described previously [45] . HSV-1 and -2 stocks were prepared from infected Vero cells as described earlier [46] .
The titres of influenza A/WSN/1933 wild-type and mutant strains were determined on MDCK cells by plaque assay [26] . Influenza A/Udorn/1972 titre was determined using plaque assay and hemagglutination assay as described previously [42] . Influenza B virus titre was determined by indirect immunofluorescence staining with a nucleoprotein (NP)-specific antibody as described previously [26] . EV1 and EV6 titres were determined by endpoint titration method described in [47] . HSV-1 and HSV-2 titres were determined by plaque titration in Vero cells in the presence (cat #: 11344784; specific activity: < 0.01 ngÁmL À1 ), rh IL-28A (cat #: 11340280; specific activity: not specified), and rh IL-29 (cat #: 11340290; specific activity: not specified) were from ImmunoTools, Germany. IFNs were dissolved in deionized sterile water to obtain 100 lgÁmL À1 concentrations. The reagents were stored at À80°C.
Antiviral agents, IDO inhibitors and siRNAs
Saliphenylhalamide was synthesized as described in [49] . Obatoclax, gemcitabine, SNS-032, epacadostat and NLG919 were from Selleck Chemicals, USA. JNJ872 was from Janssen, USA. Compounds were dissolved in 100% dimethyl sulfoxide (Sigma-Aldrich) to obtain 10 mM stock solutions and stored at À80°C. Pan H1N1 neutralizing HA antibody (6F12) was produced as described in [28] . 
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Cells
Human primary macrophages were obtained from leucocyte-rich buffy coats from healthy blood donors under permission from the Finnish Red Cross Blood Transfusion Service and the University of Helsinki Central Hospital, Finland (165/13/03/00/2011). The experiments were undertaken with the understanding and written consent of each subject. Monocytes were isolated and differentiated into macrophages as described previously [50] . Monocytes were seeded on 96-or 6-well plates and cultured in serum-free macrophage media (Gibco, Waltham, MA, USA) supplemented with 10 ngÁmL À1 granulocyte macrophage colony-stimulating factor (GM-CSF; Biosource International, Camarillo, CA, USA) and 50 UÁmL À1 penicillin-streptomycin (Lonza, Walkersville, MD, USA) at 37°C and 5% CO2 for 7 days. The media was replaced with fresh GM-CSF-free macrophage media before the macrophages were infected with or stimulated. Viral infections were carried out under BSL-2 conditions and in compliance with regulations of the University of Helsinki (permit No 21/M/09). Human RPE cells which represent excellent model system of IAV-host cell interaction were grown in Dulbecco's modified Eagle's medium (DMEM)-F12 medium supplemented with 50 UÁmL À1 PenStrep, 2 mM L-glutamine, 10%
FBS and 0,25% sodium bicarbonate (Sigma-Aldrich, St. Louis, Missouri, USA) [26] . The cells were propagated at 37°C in 5% CO 2 . RPE cells were cultured to 80% confluency in 24-well plates and transfected with 100 nM specific or control siRNA using Lipofectamine Ò RNAiMAX Reagent (Thermo Fisher Scientific, Waltham, MA, USA). Twenty-four hours after transfections, the cells were infected with WSN or mock using virus growth medium (VGM) containing 0.2% BSA (Sigma-Aldrich), 2 mM Lglutamine, 0.348% NaHCO3 and 1 lgÁmL À1 L-1-tosylamide-2-phenylethyl chloromethyl ketone-treated trypsin (TPCK)-trypsin (Sigma-Aldrich) in DMEM-F12. Ten hours after infection, the levels of genes of interest were analysed using RT-qPCRs.
Cell viability and compound efficacy assay
The cell viability and compound efficacy were analysed with the Cell Titer Glo assay (CTG; Promega, Madison, WI, USA) at 24 hpi as descried previously [26, 33, 36] . The 50% cytotoxic concentrations (CC 50 ) and the half maximal effective concentrations (EC 50 ) for obatoclax, SNS-032, SaliPhe, gemcitabine and JNJ-872 were reported previously [26, 33, 36] . The CC50 and EC50 values for epacadostat were 10 lM and > 30 lM, and for NLG919 were 5 lM and > 30 lM respectively.
Gene expression profiling and reversetranscription quantitative polymerase chain reaction (RT-qPCR)
We analysed the gene expression data from this or our previous studies (GEO accession numbers: GSE79854, GSE62127, GSE66015, GSE65699; ArrayExpress accession number: E-MTAB-4891) [24] [25] [26] 33, 35, 36] . In those studies, the total RNA was extracted from infected macrophages 8 h post infection or from infected mice 3 days post infection. Human and mice gene expression analyses were performed using Illumina HumanHT-12 V4.0 or Agilent's 4 9 44K (G4122F) whole mouse genome microarray kits, respectively. The data analysis was performed using R (version 3.2.2), Boston, MA, USA and R studio (Version 0.99.486). Raw Illumina transcriptomics data were normalized using quantile normalization with normalize.quantiles function from Bioconductor's preprocessCore package (www.bioconductor.org/packages//2.7/bioc/html/ preprocessCore.html). The data were log2 transformed. Differential expression analysis of the normalized data was performed using the LIMMA package implemented in Bioconductor by employing an empirical Bayes t-test [51] . Infections/treatments were indicated in the design matrix for the linear fitting. The Benjamini-Hochberg method was used to adjust P-values for multiple hypothesis testing. Heatmap for transcriptomics data was generated using the pheatmap package (https://cran.r-project.org/web/packages/pheatmap/index. html) based on log2 transformed expression data and hierarchical clustering of genes and samples in the heatmap was generated using the complete-linkage clustering method and Euclidian distances. Genes from tryptophan metabolism were derived from REACTOME database (www.reactome.org/).
RT Technical triplicates of each sample were performed on the same qPCR plate and nontemplates and nonreverse transcriptase samples were analysed as negative controls. The relative gene expression was analysed as described previously [33] and the results were presented as relative units (RU). The data were log2 transformed and t-test was used to calculate FCs and P-values for differentially expressed genes. The Benjamini-Hochberg method was used for Pvalue adjustments.
Immunoblotting
For immunoblot analysis, macrophages were infected with influenza A/Udorn/1933 virus at multiplicity of infection (moi) 1. At different time points post infection, the media was removed; cells were lysed in 29 SDS sample buffer, and sonicated to dissolve aggregates. Proteins were resolved by electrophoresis in gradient 4-20% SDS/PAGE gels (Biorad) and transferred to polyvinylidene fluoride membrane (GE Healthcare, Little Chalfont, UK). Membranes were blocked with 5% BSA (Sigma-Aldrich) in Tris-buffered saline (TBS) for 1 h at room temperature and incubated with primary rabbit anti-NS1 (1 : 5000; from I. J. laboratory, Turku, Finland), rabbit anti-NP (1 : 5000; from I. J. laboratory), rabbit anti-IDO (1 : 1000; Cell Signaling #12006; Danvers, MA, USA) or rabbit anti-GAPDH (1 : 1000; Santa Cruz, sc-47724; Dallas, TX, USA) antibody overnight at +4°C. Membranes were washed three times for 10 min with TBS buffer containing 0.5% Tween 20 (Tween/TBS) and incubated for 1 h at room temperature with secondary antibodies. After three washes for 10 min with Tween/TBS buffer and one with TBS, membranes were scanned on an Odyssey scanner (Li-Cor Biosciences, Lincoln, NE, USA).
Mouse experiments
In the present study, we used mouse lungs which were prepared as described in [24, 25] 
Metabolomics analysis
Metabolomics analysis was performed as described previously [36] . Briefly, 10 lL of labelled internal standard mixture was added to 100 lL of the sample (macrophage media, cell lysates or mouse lung homogenates). About 0.4 mL of solvent (99% ACN and 1% FA) was added to each sample. Insoluble fraction was removed by centrifugation (14 000 rpm, 15 min, 4°C). The extracts were dispensed in Ostro TM 96-well plate (Waters Corporation, Milford, MA, USA) and filtered by applying vacuum at a delta pressure of 300-400 mbar for 2.5 min on Hamilton StarLine robot's vacuum station. The clean extract was collected in a 96-well collection plate, and placed under the Ostro TM plate. The collection plate was sealed and centrifuged for 15 min, 4000 rpm, 4°C and placed in auto-sampler of the liquid chromatography system for the injection. Sample analysis was performed on an Acquity UPLC-MS/MS system (Waters Corporation). The auto-sampler was used to perform partial loop with needle overfill injections for the samples and standards. The detection system, a XevoÒ TQ-S tandem triple quadrupole mass spectrometer (Waters), was operated in both positive and negative polarities with a polarity switching time of 20 msec. Electro spray ionization (ESI) was chosen as the ionization mode with a capillary voltage at 0.6 KV in both polarities. The source temperature and desolvation temperature of 120 and 650°C, respectively, were maintained constantly throughout the experiment. Declustering potential (DP) and collision energy (CE) were optimized for each compound. Multiple reaction monitoring (MRM) acquisition mode was selected for quantification of metabolites with individual span time of 0.1 s given in their individual MRM channels. The dwell time was calculated automatically by the software based on the region of the retention time window, number of MRM functions and also depending on the number of data points required to form the peak. MassLynx 4.1 software was used for data acquisition, data handling and instrument control. Data processing was done using TargetLynx software and metabolites were quantified by calculating curve area ratio using labelled internal standards (IS) (area of metabolites/area of IS) and external calibration curves. Metabolomics data were log2 transformed for linear modelling and empirical Bayes-moderated t-tests using the LIMMA package [52] . To analyse the differences in metabolites levels, a linear model was fit to each metabolite. The Benjamini-Hochberg method was used to correct for multiple testing. The significant metabolites were determined at a Benjamini-Hochberg false discovery rate (FDR) controlled at 10%. The heatmap for all the metabolites was generated using the pheatmap package (https://cran.r-project.org/web/package s/pheatmap/index.html) based on log2-transformed profiling data. REACTOME pathway analysis tool was used to retrieve tryptophan metabolites (www.reactome.org/).
